T cell Bim is a marker for cancer patient's responses to anti-PD-1 immunotherapy

“

We are addressing some fundamental questions in cancer immunotherapy: How to identify tumor-reactive T cell responses in cancer patients; Why some cancer patients benefit from anti-PD-1 immunotherapy and some do not. This study basically provided two methods for these questions: 1st, PD-1 and CD11a expression can be used as a marker to identify human tumor-reactive CD8 T cells; 2nd, T cell Bim levels can reflect different responses to anti-PD-1 therapy in cancer patients.

”